What is the impact of microvascular complications of diabetes on severe COVID-19?

被引：8

作者：

Basra, Ruman ^{[1
]}

Whyte, Martin ^{[2
,3
,4
]}

Karalliedde, Janaka ^{[1
,4
]}

Vas, Prashanth ^{[3
,4
]}

机构：

[1] Kings Coll London, Sch Cardiovasc Med & Sci, London, England

[2] Univ Surrey, Dept Clin & Expt Med, Guildford, Surrey, England

[3] Kings Coll NHS Fdn Trust, Dept Diabet, London, England

[4] Kings Hlth PartnersInst Diabet Endocrinol & Obes, London, England

来源：

MICROVASCULAR RESEARCH | 2022年 / 140卷

关键词：

COVID-19; Diabetes; Microvascular disease; Endothelial dysfunction; Retinopathy; Albuminuria; Diabetic nephropathy; ENDOTHELIAL DYSFUNCTION; RISK-FACTORS; RETINOPATHY; MELLITUS; MICROALBUMINURIA; ASSOCIATION; NEPHROPATHY; PREVALENCE; MECHANISMS; MORTALITY;

D O I：

10.1016/j.mvr.2021.104310

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Evidence suggests severe coronavirus disease-19 (COVID-19) infection is characterised by pulmonary and systemic microvasculature dysfunction, specifically, acute endothelial injury, hypercoagulation and increased capillary permeability. Diabetes, which is also characterised by vascular injury in itself, confers an increased risk of adverse COVID-19 outcomes. It has been suggested that pre-existing endothelial dysfunction and microvascular disease in diabetes will exacerbate the vascular insults associated with COVID-19 and thus lead to increased severity of COVID-19 infection. In this article, we evaluate the current evidence exploring the impact of microvascular complications, in the form of diabetic retinopathy and nephropathy, in individuals with COVID-19 and diabetes. Future insights gained from exploring the microvascular injury patterns and clinical outcomes may come to influence care delivery algorithms for either of these conditions.

引用

页数：7

共 50 条

[1] Microvascular disease in diabetes and severe COVID-19 outcomes
Corcillo, Antonella
Whyte, Martin B.
Vas, Prashanth
Karalliedde, Janaka
[J]. LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (04): : 200 - 201
[2] Microvascular disease in diabetes and severe COVID-19 outcomes Reply
Colhoun, Helen M.
McGurnaghan, Stuart J.
McKeigue, Paul M.
[J]. LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (04): : 201 - 201
[3] Impact of untreated diabetes and COVID-19-related diabetes on severe COVID-19
Ushigome, Emi
Hamaguchi, Masahide
Sudo, Kazuki
Kitagawa, Nobuko
Kondo, Yuriko
Imai, Dan
Hattori, Tomohito
Matsui, Takaaki
Yamazaki, Masahiro
Sawa, Teiji
Fukui, Michiaki
[J]. HELIYON, 2022, 8 (01)
[4] Severe COVID-19 Is a Microvascular Disease
Lowenstein, Charles J.
Solomon, Scott D.
[J]. CIRCULATION, 2020, 142 (17) : 1609 - 1611
[5] Analysis of microvascular and neurodegenerative complications of mild COVID-19
Kolkedi, Zsofia
Csutak, Adrienne
Szalai, Eszter
[J]. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2022, 260 (08) : 2687 - 2693
[6] COVID-19 and the hidden threat of diabetic microvascular complications
Zaghloul, Hadeel
Malik, Rayaz A.
[J]. THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2022, 13
[7] Analysis of microvascular and neurodegenerative complications of mild COVID-19
Zsofia Kolkedi
Adrienne Csutak
Eszter Szalai
[J]. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260 : 2687 - 2693
[8] COVID-19: Impact of and on Diabetes
Jonathan Schofield
Lalantha Leelarathna
Hood Thabit
[J]. Diabetes Therapy, 2020, 11 : 1429 - 1435
[9] COVID-19: Impact of and on Diabetes
Schofield, Jonathan
Leelarathna, Lalantha
Thabit, Hood
[J]. DIABETES THERAPY, 2020, 11 (07) : 1429 - 1435
[10] In vivo demonstration of microvascular thrombosis in severe COVID-19
Douglas Alexandre do Espírito Santo
Anna Cristina Bertoldi Lemos
Carlos Henrique Miranda
[J]. Journal of Thrombosis and Thrombolysis, 2020, 50 : 790 - 794

← 1 2 3 4 5 →